Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor. Issue 6 (25th June 2021)

• Record Type: Journal Article
• Authors: Chu, Ling-Yu; Zhou, Jian-Yuan; Zhao, Yi-Xuan; Ou, Yan-Ting; Yang, Tian; Peng, Yu-Hui; Fang, Wang-Kai; Xu, Yi-Wei; Xie, Jian-Jun
• Is Part Of: Bioscience reports. Volume 41:Issue 6(2021)
• Publication Date: 2021-06-25
• Subjects: CYR61 -- diagnosis biomarker -- esophagogastric junction tumor -- serum biomarker; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20204117
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Background: Esophagogastric junction tumor (EGJ) is a rare but fatal disease with a rapid rising incidence worldwide in the late 20 years, and it lacks a convenient and safe method for diagnosis. The present study aimed to evaluate the potential of serum CYR61 as a biomarker for the diagnosis of EGJ tumor. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to estimate CYR61 levels in sera of 152 EGJ tumor patients and 137 normal controls. Receiver operating characteristics (ROC) was carried out to evaluate the diagnostic accuracy. The Mann–Whitney's U test was used to compare the difference of serum levels of CYR61 between groups. And chi-square tests were employed to estimate the correlation of the positive rate of serum CYR61 between/among subgroups. Results: Serum CYR61 levels were statistically lower in EGJ tumor and early-stage EGJ tumor patients than those in normal controls ( P <0.0001). The sensitivity, specificity and the area under the curve (AUC) of this biomarker in EGJ tumor were 88.2%, 43.8% and 0.691, respectively, and those for early stage of EGJ tumor were 80.0%, 66.4% and 0.722, respectively. Analyses showed that there was no correlation between the clinical data and the levels of CYR61 ( P >0.05). Conclusion: The present study showed that CYR61 might be a potential biomarker to assist the diagnosis of EGJ tumor.